209 results on '"Meyer, Sara C."'
Search Results
2. Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis
3. Supplementary Figure S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
4. Supplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
5. Data from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
6. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
7. Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
8. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy
9. Supplementary Data1 from Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
10. Data from Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
11. Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable
12. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
13. Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
14. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis
15. MRGPRX2: A novel biomarker in mastocytosis?
16. Escape from Type II JAK2 Inhibition in MPN Depends on AXL/MAPK Activation and Is Targetable
17. Translational implications of somatic genomics in acute myeloid leukaemia
18. Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells
19. Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis
20. Prognostic Impact of Posttransplantation Iron Overload after Allogeneic Stem Cell Transplantation
21. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia
22. Diesel exhaust particles impair platelet response to collagen and are associated with GPIbα shedding
23. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia
24. Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms
25. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
26. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
27. A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13
28. Genetics of Myeloproliferative Neoplasms
29. Interferon-γ Resistance and Immune Evasion in Glioma Develop via Notch-Regulated Co-Evolution of Malignant and Immune Cells
30. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
31. Severe cutaneous toxicity related to Eltrombopag
32. Myeloproliferative Neoplasien: Update zu Diagnostik und Therapie
33. Relations Among Family Discord, Caregiver Communication, and Childrenʼs Family Representations
34. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity
35. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation
36. In response to the comment by Hechler et al .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
37. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms
38. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
39. Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera
40. MPN patients with low mutant JAK2allele burden show late expansion restricted to erythroid and megakaryocytic lineages
41. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis
42. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
43. Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms
44. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
45. Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models
46. The Intercept Blood System Affects Platelet Function and Survival By Inducing Apoptosis
47. Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
48. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation
49. Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
50. Addition of Omega-3 α-Linolenic Acid to Platelet Apheresis Units Preserves Platelet Activatability Over Time and Reduces Baseline Activation Under Routine Storage Conditions: A Pilot Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.